MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK 2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants with Metastatic Castration -resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

16264MK-2400-01A-00-NCT06863272OpenMK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK 2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants with Metastatic Castration -resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)MK-2400-01ANCT06863272IndustrialAdultTreatmentI/IIGlobalProstateRapisuwon, SutheeMedStar Health and GUMCGenito-urinaryOncology GroupMHRI Washington Cancer Institute16794Felobateer HannaFelobateer Hannafelobateer.a.hanna@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>